Home » Supporting Your Practice » Medicine » Medically Compromised Patients

Medically Compromised Patients

Featured debbie

Hypophosphatasia: Advocating for the Patient

In the last of four segments dedicated to hypophosphatasia (HPP), Debbie Taillefer, President and Founder, Soft Bones Canada, speaks to Dr. Suham Alexander about the importance of creating a community and patient advocacy forum for patients afflicted with soft bone diseases. Highlights Soft Bones Canada was created to fill the void that Debbie and other patients required when they were newly diagnosed with HPP. Soft Bones Canada works to help support and educate patients as well as to bridge the gap with medical professionals. Dentists can play an important role in early diagnosis of the disease since the earliest signs ...

Read More »
featured bob

Hypophosphatasia: A General Dentist’s Experience

Dr. Suham Alexander speaks to Dr. Bob Schroth in this third segment about hypophosphatasia (HPP) and the dental implications and management of patients with this condition. Children with HPP have some definite dental challenges. The developing teeth in these children lack cementum on the roots which leads to premature exfoliation. Additionally, large pulp chambers and irregular dentin and enamel defects increase the extent and risk of caries development. Radiographic tell-tale signs in HPP include: enlarged pulp horns, lower bone height interproximally as well as bony defects. Prudent use of dental radiographs is recommended in these patients as determined on a ...

Read More »
Featured Cheryl

The Genetic Foundation of Hypophosphatasia

Dr. Cheryl Greenberg, a pediatrician and geneticist, speaks to Dr. Suham Alexander about the clinical history and manifestations of HPP in her unique patient population in Winnipeg, MB. HPP is over-represented in the Mennonite population in Manitoba due to a “founder” mutation. Highlights HPP is categorized by age of onset: perinatal, infant, juvenile, adult (systemic forms) and odonto-hypophosphatasia (dental form). All patients with HPP must have a low level of alkaline phosphatase. There is a strong genetic basis for the various forms of HPP. There are more than 300 mutations described in the literature. However, one gene is responsible for ...

Read More »
featured Marc 2

What is Hypophosphatasia (HPP)?

Highlights In the first segment of a 4-part series, Dr. Marc McKee introduces Oasis Discussions followers to a soft bone disease which also has a significant dental impact. Hypophosphatasia (HPP) is a very rare disease that has a prevalence of  approximately 1:100,000 live births.  Much progress has been made in recent years in understanding HPP, and in treating patients with this condition. HPP is a disease which negatively affects mineralization due to an increase in inhibitory pyrophosphate levels caused by decreased activity of an enzyme called tissue non-specific alkaline phosphatase (TNAP, TNSALP). This results in the inhibition of mineralization causing ...

Read More »
Featured tanya

COHN Webinar: Medication-Related Osteonecrosis of the Jaw (MRONJ): An Update for the Dental Practitioner

The webinar is hosted by Dr. Tanya Gibson. The webinar explores the pathogenesis and risk factors of medication-related osteonecrosis of the jaw. As well, it looks at the recommended management strategies based on the clinical stage at the time of presentation. Participants will learn: the pathogenesis of MRONJ. risk factors for developing MRONJ. the clinical staging of MRONJ. management strategies for MRONJ. To register and attend the webinar, you can find more information here   Dr. Tanya Gibson DDS Tanya Marie Gibson, DDS, a native of Cleveland, Ohio, is an assistant professor at the University of Missouri Kansas City (UMKC) ...

Read More »
Featured Debbie

Oral Care in Cancer Therapy: Oral Care After Head & Neck Cancer Treatment

Drs. Deborah Saunders and Joel Epstein return to Oasis Discussions to discuss a third complication that occurs during cancer therapy and beyond, xerostomia. Xerostomia affects speech, chewing, swallowing, taste and overall nutrition which may negatively affect overall treatment and patient outcomes during therapy. Xerostomia is not related to aging as much as it reflects the use of medications that result in dry mouth. See also: Oral Care in Cancer Therapy Part 1: Oral Care Pre-Head & Neck Cancer TreatmentOral Care in Cancer Therapy Part 2: Oral Care During Cancer Therapy Functions of Saliva Antimicrobial activity Control of pH Removal of ...

Read More »
Featured Debbie

Oral Care in Cancer Therapy: Oral Care During Cancer Therapy

This second segment of the six-part series of oral complications in cancer treatment deals with fungal infections, most commonly candidiasis. See also: Oral Care in Cancer Therapy Part 1: Oral Care Pre-Head & Neck Cancer TreatmentOral Care in Cancer Therapy Part 3: Oral Care During Cancer Therapy Candidiasis or condidosis is an overgrowth of a commensal organism. The infection usually involves C. albicans, but C. krusei, dublinensis and torolopsilosis are also seen. It is important to note that resistance has been noted to medications by Candida spp. Etiology Due to systemic immune effects Extremes of age Malnutrition Cytotoxic CT Immune T-cell defects (HIV, ...

Read More »
Featured Debbie

Oral Care in Cancer Therapy: Oral Care Pre-Head & Neck Cancer Treatment

Drs. Deborah Saunders and Joel Epstein return to Oasis Discussions to discuss oral care before, during and after head and neck cancer treatment. See also: Oral Care in Cancer Therapy Part 2: Oral Care During Cancer TherapyOral Care in Cancer Therapy Part 3: Oral Care After Head & Neck Cancer Treatment Cancer is the leading cause of mortality in the world and it is expected to continue to grow. Infection-related cancers such as HPV, EBV and HCV are expected to play an important role in this increase. It is forecasted that a dentist will see ~1.3 newly diagnosed case of ...

Read More »